comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism Beyond glycemia: Comparing tirzepatide to

These EECs are classified based on the hormones they produce, such as serotonin-producing enterochromaffin cells (ECs), cholecystokini (CCK)-producing I-cells, GIP-producing K-cells, GLP-1 producing L-cells, somatostatin (SST)-producing D-cells, neurotensin (NTS)-producing N-cells, secretin (SCT)-producing S-cells and ghrelin (GHRL)-producing X cells

2 In the full study population, breast cancer was diagnosed in 1.62% (247/15,264) of women with GLP-1 exposure compared with 2.47% (2,381/96,382) of women without exposure, corresponding to an odds ratio (OR) of 0.649 (95% CI, 0.5690.741

Many Reddit users report GLP-1 side effects such as constipation, diarrhea, fatigue, low appetite, and nausea

The typical retatrutide titration for GLP-1 naive individuals starts at 1mg weekly

GLP-1RAs work to stimulate insulin secretion in a glucose-dependent manner, thus carrying a low risk of hypoglycemia

doi:10.6065/apem.2017.22.1.15 Doyle ME, Egan JM